KEYNOTE-052: 5-Yr Update of First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.
Format: Microsoft PowerPoint (.ppt)
File Size: 478 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Phase I/II EV-103 cohort K: enfortumab vedotin with or without pembrolizumab as first-line treatment in cisplatin-ineligible locally advanced urothelial cancer, presented at ESMO and reported by Clinical Care Options (CCO)

Released: September 22, 2022

CheckMate 274: pretreatment tumor and immune features and DFS with adjuvant nivolumab in high-risk muscle-invasive UC following radical resection, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Results from CheckMate 914 (Part A): adjuvant nivolumab plus ipilimumab vs placebo in resected stage II/III clear-cell RCC at high risk of recurrence, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings